Clinical Trial Detail

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT05059470
Title	IMRT Followed by Pembrolizumab in the Adjuvant Setting in Anaplastic Cancer of the Thyroid (IMPAACT): Phase II Trial Adjuvant Pembrolizumab After IMRT in ATC
Recruitment	Recruiting
Gender	both
Phase	Phase II
Variant Requirements	Yes
Sponsors	M.D. Anderson Cancer Center
Indications	anaplastic thyroid carcinoma
Therapies	Pembrolizumab
Age Groups:	senior \| adult
Covered Countries	USA